VERAXA Biotech (NASDAQ: VRXA) an emerging developer of novel cancer therapies, announced it has expanded its laboratory footprint at its existing research and development site in Heidelberg, Germany, under a previously executed long-term lease agreement. The additional space will support planned growth of the company’s R&D team, installation of new laboratory equipment and completion of infrastructure needed to advance future development activities.
VERAXA said the expansion aligns with efforts to advance its growing portfolio of proprietary and partnered oncology programs from discovery-stage research toward early clinical development. The company’s pipeline is centered on its BiTAC platform, including BiTAC-TCE and BiTAC-ADC candidates, which are designed to enable tumor-restricted activation of cancer therapies through the use of complementary precursor molecules.
To view the full press release, visit https://nnw.fm/n3t6U
About VERAXA Biotech AG (NASDAQ: VRXA)
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at http://nnw.fm/VRXA
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
